Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients

摘要: In recent years inhibitors directed against the epidermal growth factor receptor (EGFR) have evolved as effective targeting cancer drugs. Characteristic papulopustular exanthemas, often described acneiform rashes, are most frequent adverse effect associated with this class of novel drugs and develop in > 90% patients. Notably, rash may significantly compromise patients' quality life, thereby potentially leading to incompliance well dose reduction or even termination anti-EGFR therapy. Yet, an dermatologic management cutaneous effects can be achieved. Whereas various case reports, series expert opinions on EGFR-inhibitor (EGFRI) induced rashes been published, data systematic studies sparse. Here, we present a retrospective, uncontrolled, comparative study 49 patients three established regimens for EGFRI-associated rashes. Strikingly, severity improved over weeks treatment topical mometason furoate cream, prednicarbate cream plus nadifloxacin systemic isotretinoin. summary our results demonstrate that effectively managed by specific interventions. mild moderate should treated basic measures combination glucocorticosteroids combined regiments using antiseptics/antibiotics, more severe therapy-resistant likely respond addition retinoids.